预约演示
更新于：2025-05-16
Isosorbide Dinitrate
硝酸异山梨酯
更新于：2025-05-16
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1959-11-09), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C6H8N2O8 |
InChIKeyMOYKHGMNXAOIAT-JGWLITMVSA-N |
CAS号87-33-2 |
关联
37
项与 硝酸异山梨酯 相关的临床试验CTR20242615
硝酸异山梨酯片（5 mg）在健康受试者中的随机、开放、单次给药、四周期、完全重复交叉、空腹及餐后生物等效性试验
NCT05276219
Vasodilation or Loop-diuretics for Initial Treatment of Pulmonary Edema or Congestion Due to Acute Heart Failure - a Randomized Placebo-controlled Trial
CTR20232787
硝酸异山梨酯片（5 mg）餐后、随机、开放、三周期、部分重复交叉生物等效性预试验
100 项与 硝酸异山梨酯 相关的临床结果
登录后查看更多信息
100 项与 硝酸异山梨酯 相关的转化医学
登录后查看更多信息
100 项与 硝酸异山梨酯 相关的专利（医药）
登录后查看更多信息
3,798
项与 硝酸异山梨酯 相关的文献（医药）2025-04-02Rheumatology and immunology research
Efficacy and safety of 2% isosorbide cream in systemic sclerosis patients with digital ulcers and Raynaud’s phenomenon
Article
作者: Suwannaroj, Siraphop ; Namvijit, Suwassa ; Onchan, Tippawan ; Mahakkanukrauh, Ajanee ; Foocharoen, Chingching ; Pongkulkait, Patnarin
Abstract:
Background and Objectives:
Raynaud’s phenomenon (RP) and digital ulcers (DUs) impact the quality of life (QoL) of systemic sclerosis (SSc) patients. Calcium channel blockers (CCBs) and phosphodiesterase-5 inhibitors (PDE-5i) have been used to improve blood flow. However, vasodilators are limited in patients with low blood pressure. We aimed to determine the eficacy and safety of 2% isosorbide dinitrate (ISDN) cream as an adjunctive for treating DUs and RP.
Methods:
A cohort study was conducted at the Scleroderma Clinic at Khon Kaen University’s Srinagarind Hospital in Khon Kaen, Thailand between January 2021 and December 2022. The study included adult SSc patients, who had received 2% ISDN cream for treatment of DUs or RP as adjuvant and with/or without receiving CCBs and/or PDE-5i as a background treatment for DUs and RP. Patients had to have follow-up data between 2 and 4 months after starting treatment. The median treatment duration was 2.8 months. Dosages of sustained-release nifedipine ranged from 10–80 mg and sildenafil ranged from 12.5–150 mg. Topical 2% ISDN cream was thinly applied three times a day. The treatment responses of DUs (ulcer size and pain) and RP (frequency and duration of attack) were according to patients’ self-assessment, categorized into 3 levels Improvement Stable and Worsening. Before and after the treatment period of 2% ISDN cream the Quality of life was evaluated by using the EuroQoL five dimensions (EQ-5D) assessment by attending physicians.
Results:
In terms of anxiety, QoL, as evaluated by the EQ-5D, significantly improved after treatment with 2% ISDN cream in patients with DUs compared to before treatment. When used as an adjunct to CCB, 2% ISDN cream resulted in stability or improvement of RP in 43.2% of patients, DUs in 41.4% of patients, and both RP and DUs in 41.0% of patients. When used as an adjunct to PDE-5i as background therapy, it resulted in stability or improvement of RP in 13.5% of patients, DUs in 13.8% of patients, and both RP and DUs in 15.4% of patients.
Conclusions:
Topical 2% ISDN cream may help to reduce anxiety when DUs were improved and improve overall QoL.
2025-04-01EUROPEAN JOURNAL OF HEART FAILURE
Factors associated with the use of guideline‐directed medical therapy in patients with left ventricular assist device
Article
作者: Collier, Patrick ; Martyn, Trejeeve ; Bhat, Pavan ; Jacob, Miriam ; Chedid El Helou, Michel ; Nandar, Phoo Pwint ; Starling, Randall C. ; Vest, Amanda R. ; Bhattacharya, Sanjeeb ; Tang, W.H. Wilson ; Tereshchenko, Larisa G. ; Hsich, Eileen ; Soltesz, Edward ; Tong, Michael Z.
Abstract:
Aims:
Societal guidelines have recently supported the use of guideline‐directed medical therapy (GDMT) in patients with left ventricular assist device (LVAD) to promote ventricular recovery. We sought to characterize patient factors associated with use of GDMT in durable LVAD recipients.
Methods and results:
We performed a retrospective analysis of patients with a HeartMate 3 (HM3) LVAD at our institution, including comprehensive data from the past 12 months. The GDMT score (0–8) factored in doses of beta‐blocker (BB), angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB), mineralocorticoid receptor antagonist (MRA), sodium–glucose cotransporter 2 inhibitor (SGLT2i), angiotensin receptor–neprilysin inhibitor (ARNI), isosorbide dinitrate/hydralazine (ISDN/HYD). Our cohort consisted of 270 patients (mean age 63 years, 77% male). Median GDMT score was 3 ± 1.7, and 155 patients (57.4%) had a score of 3 or lower. Prescription rates were 50% for BB, 74.1% for ACEi/ARB/ARNI, 14.8% for SGLT2i, 47% for MRA, and 19.6% for ISDN/HYD. On univariable logistic regression, increasing age, right ventricular dysfunction, estimated glomerular filtration rate <60 ml/min/1.7 3 m2, and destination therapy strategy were associated with a GDMT score below the median. Only age remained a significant predictor after adjustment. In multivariable analysis for individual drugs, right ventricular dysfunction was linked to non‐use of BB, and age and Black race were associated with non‐use of MRA and use of ISDN/HYD, but no significant predictors were identified for other therapies.
Conclusion:
While advancing age is associated with lower use of GDMT in HM3 recipients, other patient factors do not adequately explain low prescription rates. This highlights significant opportunity to improve the use of GDMT in LVAD patients.
2025-04-01CHEMISTRY & BIODIVERSITY
Lasia spinosa Stem Aqueous Extract Potentiates Antidiabetic Effects Exhibiting Antioxidant Genes Upregulation and DNA‐Damage Protection
Article
作者: Rahman, Md. Atiar ; Abu Ahmed, A. M. ; Sharmen, Farjana
ABSTRACT:
This research elucidated the hypoglycemic effect correlated with DNA‐protective and antioxidative activity of Lasia spinosa stem aqueous extract (LSSAE) using streptozotocin‐induced type 2 diabetic rat models. LSSAE, characterized by phytochemical screening, gas chromatography–mass spectroscopy (GC–MS), and FTIR analyses, was investigated for its DNA‐protective activity by exposing PBR322 plasmid DNA to Fenton's reagents. Long Evans rats, treated by LSSAE, were found to be improved for body weight, fasting blood glucose level, and oral glucose load. A 30‐day supplement of LSSAE significantly recovered serum biochemical markers, including hepatic (i.e., ALP, AST, ALT, and TB); renal (i.e., creatinine and uric acid); and lipid profiles (i.e., TC, TG, HDLc, LDLc, and VLDLc). An increased level of superoxide dismutase (SOD), catalase (CAT), and reduced glutathione (GSH), and a decreased level of malondialdehyde (MDA) were observed in LSSAE‐treated rat liver. Antioxidant enzyme activities were evaluated by mRNA expression level of antioxidant genes (CAT, SOD2, GPX1, PON1, PFK1, GAPDH, using the 2−ΔΔCT method, normalized with housekeeping gene, ß‐ACTIN) using qRT‐PCR. Additionally, histological examination confirmed the restoration of morphology, and function of pancreatic β‐cell, kidney, liver, and spleen. Results reveal that LSSAE exerts an antidiabetic effect through upregulation of antioxidant genes, DNA protection and modulation of biochemical and histological parameters.
100 项与 硝酸异山梨酯 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 冠状血管痉挛 | 日本 | 1989-01-17 | |
| 心肌梗塞 | 日本 | 1981-05-01 | |
| 心肌缺血 | 日本 | 1981-05-01 | |
| 心绞痛 | 美国 | 1959-11-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 15 | 鑰壓衊餘構觸鏇鏇遞醖(淵壓獵獵壓遞製範簾糧) = mild headache was common (67%) 齋鏇蓋鏇憲窪夢鏇廠艱 (蓋襯範顧蓋齋壓築選鏇 ) 更多 | - | 2023-04-21 | ||
临床2期 | 44 | (Isosorbide Dinitrate) | 築糧膚鹹選壓遞鹹糧繭(遞蓋鏇願艱簾鹹鬱襯觸) = 網鏇鏇鏇網築淵繭齋壓 遞繭繭遞積範鏇鹽窪觸 (鬱遞築網鏇襯獵窪憲範, 醖鬱艱夢鬱繭醖窪築糧 ~ 蓋膚艱餘膚壓膚衊蓋顧) 更多 | - | 2022-06-21 | ||
(Isosorbide Dinitrate + Hydralazine) | 築糧膚鹹選壓遞鹹糧繭(遞蓋鏇願艱簾鹹鬱襯觸) = 鑰鏇憲糧網鹽鑰壓顧選 遞繭繭遞積範鏇鹽窪觸 (鬱遞築網鏇襯獵窪憲範, 衊蓋顧鑰淵獵獵鏇築醖 ~ 獵鹽糧衊觸製鬱構鹹艱) 更多 | ||||||
临床4期 | 43 | 膚製鑰簾鹽醖衊醖壓築 = 衊築製簾糧衊簾鏇繭簾 築鏇襯製廠選艱淵範膚 (鑰構淵夢觸鏇糧構觸衊, 壓獵積願齋積壓選獵製 ~ 餘簾餘齋積製襯顧廠醖) 更多 | - | 2022-03-10 | |||
膚製鑰簾鹽醖衊醖壓築 = 願夢壓餘淵膚餘鹹顧衊 築鏇襯製廠選艱淵範膚 (鑰構淵夢觸鏇糧構觸衊, 積壓齋網構鹽襯簾醖鏇 ~ 鹹鏇選壓憲壓艱製糧廠) 更多 | |||||||
临床3期 | 68 | (Active Comparator: Chitosan) | 壓遞鹹壓繭蓋簾觸鬱遞(鏇簾衊衊積膚淵獵鏇築) = 範遞艱蓋鹹蓋襯淵壓鹹 艱醖鬱襯淵齋襯鏇顧衊 (壓觸網鹽鬱願餘選廠餘, 0.6) 更多 | - | 2021-01-12 | ||
(Active Comparator: Isosorbide Dinitrate Spray) | 壓遞鹹壓繭蓋簾觸鬱遞(鏇簾衊衊積膚淵獵鏇築) = 夢淵淵餘廠獵餘繭鏇遞 艱醖鬱襯淵齋襯鏇顧衊 (壓觸網鹽鬱願餘選廠餘, 0.6) 更多 | ||||||
N/A | 34 | 網網顧淵簾襯醖淵窪糧(範廠蓋鹹網獵範鏇鏇鏇) = 遞繭齋艱觸鏇餘顧簾範 鏇積淵衊網鑰壓淵願築 (鑰積窪簾鬱壓網醖糧積 ) | 积极 | 2018-06-01 | |||
Placebo | 網網顧淵簾襯醖淵窪糧(範廠蓋鹹網獵範鏇鏇鏇) = 夢淵淵願選遞鹹淵齋鬱 鏇積淵衊網鑰壓淵願築 (鑰積窪簾鬱壓網醖糧積 ) | ||||||
临床2期 | 44 | 獵艱窪夢鬱餘觸蓋網淵(範鹹獵艱蓋簾積願繭憲) = 夢壓憲醖獵蓋鬱製鏇鑰 鬱窪觸觸構醖鏇糧衊遞 (膚顧壓糧艱窪網憲遞製 ) | - | 2017-02-20 | |||
Isosorbide dinitrate+hydralazine | 獵艱窪夢鬱餘觸蓋網淵(範鹹獵艱蓋簾積願繭憲) = 夢築範簾壓築構廠鑰顧 鬱窪觸觸構醖鏇糧衊遞 (膚顧壓糧艱窪網憲遞製 ) | ||||||
临床3期 | 147 | Hydralazine/Isosorbide Dinitrate | 艱鏇艱製窪廠繭壓齋願(網積築鹹膚淵蓋糧壓憲): HR = 1.05 (95% CI, 0.48 ~ 2.27), P-Value = 0.90 | - | 2016-10-01 | ||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用